Prevalence and risk factors for impaired awareness hypoglycemia and severe hypoglycemia prevention study

Conditions

Type 1 diabetes, type 2 diabetes with basal-bolus insulin therapy

Sakane N, Kato K, Hata S, Nishimura E, Araki R, Kouyama K, Hatao M, Matoba Y, Matsushita Y, Domichi M, Suganuma A, Sakane S, Murata T.

2025-08-18

10.1007/s13340-025-00846-6

Comparing the Validity of Three Methods for Identifying Impaired Awareness of Hypoglycemia in Predicting Severe Hypoglycemia in Adults with Type 1 Diabetes Mellitus: The PR-IAH Study.

Sakane N, Kato K, Hata S, Nishimura E, Araki R, Kouyama K, Hatao M, Matoba Y, Matsushita Y, Domichi M, Suganuma A, Sakane S, Murata T.

2025-07-31

10.2169/internalmedicine.5688-25

Associations between clustering of hypoglycemic symptoms, psychological traits, and problem-solving abilities in adults with type 1 diabetes: baseline data analysis of the PR-IAH study.

Sakane N, Kato K, Hata S, Nishimura E, Araki R, Kouyama K, Hatao M, Matoba Y, Matsushita Y, Domichi M, Suganuma A, Sakane S, Murata T, Wu FL.

2025-01-16

10.1007/s13340-024-00788-5

Association of hypoglycemia problem-solving abilities with severe hypoglycemia in adults with type 1 diabetes: a Poisson regression analysis.

Sakane S, Kato K, Hata S, Nishimura E, Araki R, Kouyama K, Hatao M, Matoba Y, Matsushita Y, Domichi M, Suganuma A, Murata T, Wu FL, Sakane N.

2024-06-021 citations

10.1007/s13340-024-00733-6

Protective and risk factors of impaired awareness of hypoglycemia in patients with type 1 diabetes: a cross-sectional analysis of baseline data from the PR-IAH study

Naoki Sakane, Ken Kato, Sonyun Hata, Erika Nishimura, Rika Araki et al. (14 authors)

Diabetology & Metabolic Syndrome2023-04-246 citations

10.1186/s13098-023-01024-x

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) type 1 diabetes, type 2 diabetes with basal-bolus insulin therapy 2) diabetes duration >=1years 3) >=20 years old 4) attending a collaborating centre

Exclusion criteria

Exclusion criteria: 1) non-insulin therapy 2) anti-dementia drugs 3) inappropriate case judged by research director or research cordinators

Design outcomes

Primary

Measure	Time frame
Severe hypoglycemia	—

Secondary

Measure	Time frame
Cardiovascular disease, diabetic complications, traffic accidents, dementia, bone fracture, atrial fibrillation	—

Countries

Japan

Contacts

Public ContactAKIKO SUGANUMA

National Hospital Organization Kyoto Medical Center Clinical Research Institute

404-j-doit1@mail.hosp.go.jp075-641-9161

Outcome results